vTv Therapeutics (VTVT) Enterprise Value (2016 - 2025)
vTv Therapeutics (VTVT) has disclosed Enterprise Value for 12 consecutive years, with -$88.9 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 156.07% to -$88.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$88.9 million through Dec 2025, down 156.07% year-over-year, with the annual reading at -$88.9 million for FY2025, 156.07% down from the prior year.
- Enterprise Value hit -$88.9 million in Q4 2025 for vTv Therapeutics, up from -$98.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $54.1 million in Q1 2021 to a low of -$98.5 million in Q3 2025.
- Historically, Enterprise Value has averaged -$12.5 million across 5 years, with a median of -$623500.0 in 2022.
- Biggest five-year swings in Enterprise Value: soared 408.32% in 2023 and later tumbled 6109.43% in 2024.
- Year by year, Enterprise Value stood at $11.4 million in 2021, then plummeted by 61.23% to $4.4 million in 2022, then crashed by 176.16% to -$3.4 million in 2023, then plummeted by 927.49% to -$34.7 million in 2024, then plummeted by 156.07% to -$88.9 million in 2025.
- Business Quant data shows Enterprise Value for VTVT at -$88.9 million in Q4 2025, -$98.5 million in Q3 2025, and -$26.3 million in Q2 2025.